←
Iovance Biotherapeutics405 posts
Iovance Biotherapeutics avatar

Iovance Biotherapeutics

@IovanceBio

Iovance Biotherapeutics is dedicated to the fight against cancer.

◷ Joined February 2020▧ 245 Photos and videos
Melanoma Research Foundation avatar
⟳ Iovance Biotherapeutics retweeted
Melanoma Research Foundation@CureMelanoma·Nov 17

#TILTuesday -- Stage IV melanoma warrior, Hillary Castaneda, was diagnosed in October 2021 prior to FDA approval of a revolutionary immunotherapy known as Tumor-infiltrating lymphocyte (TIL) therapy in 2024. Following a 2025 recurrence, Hillary underwent one round of TIL therapy and a year later is showing no evidence of disease! youtu.be/tDvufNLR7ZE In this #TILTuesday installment, Hillary underscores the importance of advocating for yourself with your care team and shares her inspirational and personal advanced #melanoma journey. Hillary's story also denotes the power of innovative research and treatments such as TIL that provide hope to patients with melanoma that can't be treated with surgery alone for metastatic melanoma patients. #ProgressIsPower You can learn more about TIL therapy by visiting melanoma.org.

Iovance Biotherapeutics avatar
Iovance Biotherapeutics@IovanceBio·Nov 17

November is National Family Caregivers Month. Proud to support @MelanomaMRF’s Together Against Melanoma Patient & Caregiver Symposium with @MayoClinic. Thank you to the caregivers who show up for patients every day.💙#FamilyCaregiversMonth #Melanoma

Thank you to our incredible Together Against Melanoma Patient & Caregiver Symposium Sponsors for helping make our lifesaving mission possible. Your generosity fuels critical melanoma prevention, treatment, research, and support services for patients and caregivers. Because of you, more people have access to the knowledge, resources and community they need to navigate their melanoma journey with confidence. You still have time to register for this one-day free event that explores the latest advances in melanoma research and care. Register today: buff.ly/uO2o3Di

Post attachment
Iovance Biotherapeutics avatar
Iovance Biotherapeutics@IovanceBio·Nov 11

Thank you to our veterans, and to the Iovance colleagues who served. 🎗️ Melanoma is the 4th most common #cancer among #veterans. This #VeteransDay, help protect their health by spreading #MelanomaAwareness. Watch one veteran’s story: news.vumc.org/2026/10/28/mor…

John E. Mullinax, MD, FACS avatar
⟳ Iovance Biotherapeutics retweeted
John E. Mullinax, MD, FACS@JohnEMullinaxMD·Nov 8

We're excited to be one of only two sites currently enrolling on the @IovanceBio SARATOGA Trial. Trial design is based on exciting results presented at #SITC26 by Lauren Banks, MD PhD from @MSKCancerCenter Prescreen and contact us: moffitt.org/clinical-trials-… @liposarcoma_sn

At #SITC26, John Mullinax, MD (@JohnEMullinaxMD), highlights the SARATOGA TIL study, in which Moffitt participated as a clinical trial site. He touches on the study's clinical endpoints and the importance of industry collaboration in advancing treatment options for patients with sarcoma. #MoffittSITC26

0:33
Iovance Biotherapeutics avatar
Iovance Biotherapeutics@IovanceBio·Oct 29

🔔Today, Iovance announced updated Phase 2 IOV-LUN-202 data in metastatic non-squamous non-small cell lung 🫁cancer, along with a new biomarker-enriched strategy to guide how we develop TIL therapy in lung cancer. Read the full announcement 👉: ir.iovance.com/news-releases…

0:04